Injective sits further down the market cap rankings at #91, which weighs on the fundamentals score relative to more dominant names in the DeFi category. On-chain health is measured on fee revenue, value secured, turnover: $7k in fees over 24h (0.33% annualised against market cap), and $13.3M of value secured (2% of market cap), and 24h volume at 16.0% of market cap. That compares favourably against the rest of the rated universe.
Momentum has cooled, with price down -3.8% over the trailing 7 days. The risk pillar is holding up, with a typical daily move of about 6.1% over the past week rather than the kind of price action that signals stress.
The composite grade of B puts Injective at the 69th percentile of the rated universe on a weighted blend of fundamentals (35%), on-chain health (25%), momentum (20%), and inverted risk (20%). See the Methodology page for how each pillar is defined.
Every Antelux grade is mechanical: no analyst overrides. Each pillar below shows the exact measured input, and its score is a percentile rank against the other rated coins on that measure, so 90 means it beats 90% of the universe rather than scoring 90 out of 100. Full methodology, weightings, and grade bands are on the Methodology page.
Blends market standing with tokenomics. Rank #91 caps the sub-score; with no supply cap, emission policy is scored neutrally with a slight caution.
The composite score recorded for Injective at the end of each day. Because the score is a percentile rank within the rated universe, a flat line means Injective held its place relative to everything else, not that nothing happened to it.